Combination Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Diabetic Kidney Disease

被引：0
作者：
Robert C. Stanton
机构：
[1] Harvard Medical School,Joslin Diabetes Center, Beth Israel Deaconess Medical Center
[2] Joslin Diabetes Center,Kidney and Hypertension Section
来源：
Current Diabetes Reports | 2013年 / 13卷
关键词：
Diabetic kidney disease; ACE inhibitors; Angiotensin receptor blockers;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) have played a major role in slowing the progression of diabetic kidney disease, since they lower urine protein levels, lower blood pressure, and slow progression. Studies have suggested that the combination of ACE-I and ARB offered greater benefits for patients with diabetic kidney disease. In 2008, the large ONTARGET study reported no benefit with combination therapy, as compared with monotherapy. This study has changed practice patterns, but few patients in this study had diabetic kidney disease. In this review, the data in favor of the combination use of these agents in patients with diabetic kidney disease and data against the combination are reviewed. At this time, there is little support for using the combination in diabetic patients with no kidney disease or early stage diabetic kidney disease. But there are patients who may benefit from combination use.
引用
收藏
页码：567 / 573
页数：6
相关论文
共 108 条
[1]  
Ruggenenti P(2010)The RAAS in the pathogenesis and treatment of diabetic nephropathy Nat Rev Nephrol 6 319-330
[2]  
Cravedi P(2009)Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy? Postgrad Med 121 77-88
[3]  
Remuzzi G(2009)Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy Int Urol Nephrol 41 119-126
[4]  
Kalaitzidis R(2008)Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need? Acta Med Indones 40 34-37
[5]  
Bakris G(2004)Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in Type 1 diabetes J Renin Angiotensin Aldosterone Syst 5 33-38
[6]  
Dalla Vestra M(2002)Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension J Renin Angiotensin Aldosterone Syst 3 72-78
[7]  
Simioni N(2000)Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists Kidney Int 57 1803-1817
[8]  
Masiero A(1993)The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group N Engl J Med 329 1456-1462
[9]  
Lim S(2001)The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 870-878
[10]  
Komers R(2001)Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861-869
12345678910